A risk assessment tool developed for CAPRISA 082.
Topic(s): Research, Service Delivery
Product(s): Oral PrEP
Region(s): Sub-Saharan Africa
Format(s): Form/Template, Factsheet
Countries: South Africa
Source(s): CAPRISA
Type: Document
The PrEP Power demand generation toolkit is intended for use by local partners working with key populations (KP): men who have sex with men, trans and gender diverse people, sex workers, and people who use drugs. The PrEP Power project ran human-centered design (HCD) workshops with community members in Eswatini, Kenya, and Zambia. Everything in…
The PrEP Quiz was developed to support adolescent girls and young women to explore methods that would align with their lifestyle, needs and personal preferences; and support healthcare providers to provide informed counseling based on client needs. If you are interested in learning more or adapting this tool for use in your setting, please reach…
This plan, developed by Nigeria’s Federal Ministry of Health and Social Welfare and National Agency for the Control of AIDS, provides a roadmap for reversing the HIV epidemic in Nigeria.
This National HIV Prevention Roadmap 2026-2028 outlines Ghana’s HIV and AIDS prevention measures which are based on the five core prevention pillars -Adolescent Girls and Young Women, Adolescent Boys and Young Men, Vulnerable Populations, Condoms, and Anti-Retroviral based Prevention.
These clinical guidelines, developed by Mozambique’s Ministry of Health in 2025, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
These clinical guidelines, developed by Lesotho’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
These implementation guidelines, developed by Eswatini’s Ministry of Health in 2025, can be used to support delivery of PrEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
These clinical guidelines, developed by Kenya’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
Last update: April 2026 Visit data.prepwatch.org for a dynamic map-based tool to explore trends in PrEP use globally, including by country, product, and time period. Comprehensive datasets are available to download by clicking “download data” in the upper righthand corner. For any questions, contact [email protected]. Introduction to the Global PrEP Tracker
This website, developed and maintained by the University of Liverpool, provides clear, trustworthy, and up-to-date information about how different PrEP options, including oral PrEP, cabotegravir, lenacapavir, and the dapivirine vaginal ring, can interact with other drugs.
